Carmen Gasca-Salas obtained her medical degree from University of Zaragoza (Spain) in 2006. She pursued residency training in Neurology at Clínica Universidad de Navarra (2007-2011). She started working on her PhD in 2011 (CIBERNED grant), under the supervision of Dr. María.C. Rodríguez-Oroz and Prof. José A. Obeso at University of Navarra. This was focused on the progression of cognitive impairment in Parkinson´s disease, and included neuropsychological assessment and FDG-PET analysis. She succesfully defended her thesis in february 2016 (Excellent, Cum Laude). This study was completed with the MRI analysis during an stay at the Centre de Neuroimagerie de Recherche (CENIR), Paris, with Dr. Stephane Lehericy.
From 2011 to 2013, she worked as a clinical assistant of the Movement Disorders Unit at Clínica Universidad de Navarra with Prof. José A. Obeso. She specialized in the management of Parkinson´s disease patients including advanced therapies such as deep brain stimulation, apomorphine and intestinal levodopa gel infusions. She worked as an associate clinical professor, at Universidad de Navarra, School of Medicine. From 2013 to 2015, she continued her training as a Movement Disorders fellow with Prof. Anthony Lang at the Toronto Western Hospital, where she increased her expertise in all kind of Movement Disorders (parkinsonism, dystonia, myoclonus, tremor, ataxia, chorea, gait disorders, psychogenic/functional disorders, etc….) as well as in botulinum toxin injections for neurological conditions. She collaborated in several research projects (Dr. Anthony Lang, Dr. Susan Fox, Dr. Connie Marras, Dr. Robert Chen, Dr. Galit Kleiner-Fisman and Dr. Mario Masellis). During the second year of her fellowship (2014-2015), she also worked in the Dementia Clinic with Dr. Carmela Tartaglia and Dr. David Tang-Wai (Toronto Western Hospital). In addition, she recently did a one month rotation at St. Pau Hospital, Memory Unit (Barcelona)
Her main focus of research includes the study of imaging and clinical factors associated with cognitive impairment in early Parkinson´s disease, in order to identify patients at risk, and to understand the underlying physiopathology.
- Gasca-Salas C, Clavero P, García-García D, Obseso JA, Rodriguez-Oroz MC. Significance of visual hallucinations and cerebral hypometabolism in the risk of dementia in Parkinson’s disease with mild cognitive impairment. Human Brain Mapping. 2016 Mar;37(3):968-77
- González-Redondo R, García-García D, Clavero P, Gasca-Salas C, García-Eulate R, Zubieta JL, Arbizu J, Obeso JA, Rodríguez-Oroz MC. Grey matter hypometabolism and atrophy in Parkinson’s disease with cognitive impairment: a two-step process. Brain. 2014 Aug;137(Pt 8):2356-67. doi: 10.1093/brain/awu159. Epub 2014 Jun 20
- Gasca-Salas C, Masellis M, Khoo E, Shah BB, Fisman D, Lang AE, Kleiner-Fisman G. Characterization of movement disorder phenomenology in genetically proven, familial Frontotemporal Lobar Degeneration: A systematic review and meta-analysis. PLoS One. 2016 Apr 21;11(4):e0153852
- Garcia-Garcia D, Clavero P, Gasca-Salas C, Lamet I, Arbizu J, Gonzalez Redondo R, Obeso JA, Rodriguez-Oroz MC. “Posterior parietoccipital hypometabolism may differentiate mild cognitive impairment from dementia in Parkinson´s disease.” Eur J Nucl Med Mol Imaging 2012 Nov; 39(11): 1767-77
- Gasca-Salas C, Estanga A, Clavero P, Aguilar-Palacio I, González-Redondo R, Obeso JA, Rodríguez-Oroz MC. Longitudinal assessment of the pattern of cognitive decline in non-demented patients with advanced Parkinson’s disease. J Parkinsons Dis. 2014;4(4):677-86. doi: 10.3233/JPD-140398